Alkermes Public Limited Company (ALKS)

Alkermes Plc's stock has experienced several notable events in the past six months. The stock price increased by 23.34% over the last 12 months, with a year-to-date return of 24.27% as of April 8, 2026. The stock surged 23% in five days, reaching a 52-week high of $36.32 as of April 2, 2026. In October 2025, Alkermes reported strong third-quarter financial results, leading to raised financial expectations for 2025. Also in October 2025, Alkermes announced a proposed acquisition of Avadel Pharmaceuticals plc for $1.8 billion, which was completed in February 2026. In February 2026, Alkermes reported total revenues of approximately $1.48 billion for 2025 and provided financial expectations for 2026. CEO Richard Pops announced plans to step down in August 2026. Alkermes announced the initiation of Phase 3 Brilliance Studies evaluating alixorexton for the treatment of narcolepsy type 1 and type 2 on April 1, 2026. An insider transaction occurred on April 1, 2026, where Craig C. Hopkinson sold 9,000 Ordinary Shares.

The provided information does not explicitly detail demand seasonality for Alkermes Plc's products and services. Demand for its core products may be relatively stable rather than highly seasonal due to the company's focus on chronic conditions. The company reported strong revenue growth and underlying demand across its commercial portfolio in the third quarter of 2025.

Alkermes Plc is a global biopharmaceutical company based in Ireland, focused on developing medicines for psychiatric and neurological disorders, including addiction, mental illness, and sleep disorders. The company has a portfolio of proprietary and partnered products, including LYBALVI for schizophrenia and bipolar disorder, ARISTADA for schizophrenia, VIVITROL for alcohol and opioid dependence, and LUMRYZ for narcolepsy. Other products utilizing Alkermes' technologies include Vumerity, Risperdal Consta, and Invega Sustenna/Xeplion. The company also has a pipeline of clinical and preclinical candidates in development for neurological disorders.

Alkermes Plc is headquartered in Dublin, Ireland, with corporate offices and an R&D center in Massachusetts, U.S. Manufacturing facilities are located in Wilmington, Ohio, U.S. Previously, the company had a development and manufacturing business in Athlone, Ireland, which was sold on May 1, 2024.

Alkermes is recognized as an employer of choice in the life sciences industry, emphasizing patient-inspired science and integrated research. The company is committed to improving physician and patient education and access to medicines. In 2024, over 210,000 people were treated with LYBALVI®, the ARISTADA® product family, and VIVITROL®. No specific negative events impacting Alkermes Plc's brand reputation in the past year were found.

Alkermes Plc has significant institutional ownership, with 368 institutional owners and shareholders holding a total of 179,596,116 shares as of April 9, 2026. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Baker Bros. Advisors Lp, and State Street Corp. Institutional ownership accounts for 91.98% of the company, with individuals holding 1.56%.